Avatrombopag

(Doptelet®)

Doptelet®

Drug updated on 5/17/2024

Dosage FormTablet (oral; 20 mg)
Drug ClassThrombopoietin receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
  • Indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Avatrombopag (Doptelet) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and those with chronic immune thrombocytopenia who have had an insufficient response to previous treatments.
  • A total of 14 studies were reviewed, providing comprehensive information on Avatrombopag's safety and effectiveness compared to other thrombopoietin receptor agonists (TPO-RAs).
  • This medication has shown superior efficacy in increasing platelet counts in patients with chronic liver disease preparing for a procedure and in patients with chronic immune thrombocytopenia who had an insufficient response to prior treatments.
  • Compared to agents like eltrombopag, romiplostim, and hetrombopag, Avatrombopag demonstrated higher overall platelet response rates. It also significantly increased preoperative platelet counts while decreasing the need for transfusions without raising the rate of thrombotic events among adults undergoing procedures due to their liver condition.
  • Safety profiles across TPO-RAs do not indicate significant differences; hence, choice among these medications could be influenced more by their efficacy rather than safety concerns. However, close monitoring of potential risks, especially among elderly ITP patients or those with a history of clotting issues, is advised.
  • In terms of adverse events related specifically to Avatrombopag use, including serious ones, there was no significant difference from placebo or other TPO-RAs, indicating a similar safety profile across all groups studied.
  • The incidence rate was consistent even during short-term administration up to six months, as per subgroup analyses data available.
  • Avatrombopag appears more effective than eltrombopag in promoting better outcomes, particularly in treating adults suffering from ITP, but its comparative effectiveness remains less clearly defined within the pediatric population due to a lack of direct evidence currently available.

Product Monograph / Prescribing Information

Document TitleYearSource
Doptelet (avatrombopag) Prescribing Information.2021AkaRx, Inc., Durham, NC

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta analysis of randomized controlled trials.2024Biomedical Reports
Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.2023Expert Opinion on Pharmacotherapy
Safety of non-peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: a systematic review and meta analysis of short term double blind randomized clinical trials. 2023Experimental and Therapeutic Medicine
Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis. 2023Thrombosis Journal
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. 2023Annals of Hematology
Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study. 2023Acta Haematologica
Efficacy and incidence of treatment-related adverse events of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and network meta-analysis of randomized controlled study.2023Acta Haematologica
Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis. 2022Annals of Hematology
Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review.2021Platelets
Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis.2021Advances in Therapy
The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis.2021Platelets
Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial.2021Frontiers in Pharmacology
Therapeutic options for adult patients with previously treated immune thrombocytopenia – a systematic review and network meta-analysis.2019Hematology
Efficacy and safety of avatrombopag in patients with thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials.2019Frontiers in Pharmacology

Clinical Practice Guidelines